# To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder

> **NCT04440696** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Grand Life Science (Liaoning) Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Hyperphosphatemia

## Interventions

- **DRUG:** Lanthanum Polystyrene Sulphonate Powder
- **DRUG:** Lanthanum Carbonate 500 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04440696
- **Lead sponsor:** Grand Life Science (Liaoning) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-21
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2021-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04440696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04440696, "To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04440696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*